Par Pharma suit + IMS ruling = off-label showdown?

Par Pharmaceuticals' ($PRX) free speech lawsuit against the FDA--coupled with recent Supreme Court action--could prompt a court battle over off-label marketing. "Par's going to blow it wide open," the Coalition for Healthcare Communication's John Kamp tells Medical Marketing & Media. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.